The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 18, 2024
Filed:
Jun. 27, 2018
Viiv Healthcare Company, Wilmington, DE (US);
Janssen Sciences Ireland Unlimited Company, County Cork, IE;
Kenneth Churchill Campbell, Ware, GB;
Urbain Alfons C. Delaet, Beerse, BE;
James M. Goodrich, Research Triangle Park, NC (US);
Juliette Segolène Guaquière, Ware, GB;
Thomas Laughery, Research Triangle Park, NC (US);
Dominique J. Limet, Brentford, GB;
John C. Pottage, Collegeville, PA (US);
Ludovic Sylvain Marc Renou, Stevenage, GB;
Trevor R. Scott, Research Triangle Park, NC (US);
Christian Seiler, Brentford, GB;
Mary Woodward, Ware, GB;
ViiV Healthcare Company, Wilmington, DE (US);
Janssen Sciences Ireland UC, Little Island, IE;
Abstract
Methods are provided for treating or preventing human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) in a virologically suppressed patient in need thereof comprising switching the patient from an antiretroviral treatment regimen comprising at least three antiretroviral agents to a treatment regimen comprising only two antiretroviral agents. In one aspect the two treatment regimen consists of dolutegravir, rilpivirine and at least one pharmaceutically acceptable excipient, diluent or carrier. In another aspect of the invention, there is provided a multilayer tablet comprising dolutegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof.